Amedisys (AMED) Tops Q3 EPS by 96c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Amedisys Reports Third Quarter 2020 Financial Results - Updates 2020 Guidance
October 28, 2020 4:05 PM EDTBATON ROUGE, La., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2020.
Three-Month Periods Ended September 30, 2020 and 2019
Net service revenue increased $49.5Â million to $544.1Â million compared to $494.6Â million in 2019.Net income attributable to Amedisys, Inc. of $72.0Â million compared to $34.1Â million in 2019.Net income attributable to Amedisys, Inc. per diluted share of $2.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) compared to $1.03 in 2019.Adjusted Quarterly Results*
Adjusted EBITDA of $75.7Â million compared to $56.8Â million in... More